Concepedia
Statistics
Publications
12
Citations
908
H-Index
Active since
2020
Affiliations
University of Florida(Current)
Florida College
The University of Texas at San Antonio Health Science Center
ID Genomics (United States)
Institut thématique Génétique, génomique et bioinformatique
Vivekananda Budamagunta is an author at University of Florida specializing in apoptosis, molecular oncology, and pharmacology.
Publications per year
2020–2024
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
Yonghan He, Xuan Zhang, Jianhui Chang et al. · Nature Communications · 2020 · 257 citations · Full text
Medicine, Molecular Medicine, Pharmacology +13
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
Yonghan He, Raphael Koch, Vivekananda Budamagunta et al. · Journal of Hematology & Oncology · 2020 · 131 citations · Full text
Medicine, Cancer Biology, Oncology +14
Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity
Yonghan He, Wen Li, Dongwen Lv et al. · Aging Cell · 2020 · 113 citations · Full text
Life Sciences, Molecular Biology, Pharmacology +17
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216
Dinesh Thummuri, Sajid Khan, Patrick W. Underwood et al. · Molecular Cancer Therapeutics · 2021 · 74 citations · Full text
Medicine, Oncology, Pharmacology +16
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines
Xuan Zhang, Yonghan He, Peiyi Zhang et al. · European Journal of Medicinal Chemistry · 2020 · 64 citations · Full text
Life Sciences, Molecular Biology, Oncology +7
1–5 of 12